According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: A, and AI: C.
Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 58, which is 20 points higher than the general drug manufacturer industry average of 38.
GILD passed 21 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock return 31.66% over the past year, overperforming other general drug manufacturer stocks by 6 percentage points.
Gilead Sciences has an average 1 year
price target of $156.21, an upside of 13.49% from Gilead Sciences's current stock price of $137.64.
Gilead Sciences stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Gilead Sciences, 71.43% have issued a Strong Buy rating, 14.29% have issued a Buy, 14.29% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Bristol Myers Squibb Co (NYSE:BMY)
The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: A, Financials: B, and AI: C.
Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 46, which is 8 points higher than the general drug manufacturer industry average of 38.
BMY passed 16 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 22.22% over the past year, underperforming other general drug manufacturer stocks by -3 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $61.69, an upside of 2.52% from Bristol Myers Squibb Co's current stock price of $60.17.
Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Bristol Myers Squibb Co, 37.5% have issued a Strong Buy rating, 6.25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 6.25% have issued a Strong Sell.
3. Grifols Sa (NASDAQ:GRFS)
Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year.
Learn more.
The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: C, and AI: C.
Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 42, which is 4 points higher than the general drug manufacturer industry average of 38.
GRFS passed 15 out of 38 due diligence checks and has strong fundamentals. Grifols Sa has seen its stock return 23.59% over the past year, underperforming other general drug manufacturer stocks by -2 percentage points.
Grifols Sa has an average 1 year
price target of $10.00, an upside of 14.29% from Grifols Sa's current stock price of $8.75.
Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
